Compare SentinelOne Inc. Class A Common Stock (S) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SentinelOne Inc. Class A Common Stock vs Tango Therapeutics Inc. — how do they compare? SentinelOne Inc. Class A Common Stock trades at $22.66 (market cap $8.36B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: SentinelOne Inc. Class A Common Stock is far larger — about 2.2× Tango Therapeutics Inc.'s market cap, and SentinelOne Inc. Class A Common Stock is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SentinelOne Inc. Class A Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| S | TNGX | |
|---|---|---|
Market Cap | $8.36B | $3.75B |
Volume | 27,558,313 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $26.27 | $32.90 |
52-Week Low | $11.94 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $7.74B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SentinelOne (S) trades at $24.01, down 6.43% amid news of a $1.25 billion convertible notes offering. The stock shows bullish technical signals with strong moving average support, though oscillators remain neutral. Fundamentally, the company maintains robust revenue growth (21% YoY) and high gross margins (72.54%) but continues to report significant net losses (-$288M in 2025). Recent analyst recognition as a leader in endpoint security and expanding cloud capabilities provide positive business momentum.
Investment outlook balances strong growth potential against persistent profitability challenges. The convertible notes offering signals aggressive expansion but increases financial leverage. With 65% analyst buy ratings and a $23.42 consensus target, Wall Street remains optimistic about long-term cybersecurity demand, though investors face execution risk and competitive pressures in a capital-intensive growth phase.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SentinelOne Inc. Class A Common Stock
SentinelOne provides an AI-powered cybersecurity platform for organizations. Its Singularity platform helps detect, prevent, and respond to threats across endpoints, cloud workloads, identities, and connected devices.
Read more on S →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
